Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00035022 · ClinicalTrials.gov registry record · Phase 1
Study of Intravenous BCX-1777 in Relapsed or Refractory Aggressive T-Cell Leukemias or Lymphomas
A Phase 1 study, sponsored by BioCryst Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 71
- Enrollment target
NCT00035022: Completed Phase 1 study, sponsored by BioCryst Pharmaceuticals.
NCT00035022 is a Phase 1 study that has completed, run by BioCryst Pharmaceuticals. The registered enrollment target is 71 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (18% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00035022, a Phase 1 study, has completed, sponsored by BioCryst Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 71 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if intravenous BCX-1777 can be given safely to improve relapsed or refractory aggressive T-cell leukemias and lymphomas.
Interventions
- DRUG BCX-1777
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 71 participants |
| Start Date | 2001-08 |
| Est. Completion | 2004-03 |
| Phase | Phase 1 |
What the finished NCT00035022 record still lists
NCT00035022 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 71 participants, a relatively small participant target, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (18% higher).
The record links to 0 conditions, and to 1 intervention - of which BCX-1777 is the first listed.
NCT00035022 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00035022 about?
NCT00035022 is a clinical study titled "Study of Intravenous BCX-1777 in Relapsed or Refractory Aggressive T-Cell Leukemias or Lymphomas". The purpose of this study is to determine if intravenous BCX-1777 can be given safely to improve relapsed or refractory aggressive T-cell leukemias and lymphomas.
What is the current status of trial NCT00035022?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 71 participants. The study started on 2001-08. Estimated completion is 2004-03.
What interventions are being tested in trial NCT00035022?
The interventions under investigation include: BCX-1777 (DRUG).
Who is sponsoring clinical trial NCT00035022?
This trial is sponsored by BioCryst Pharmaceuticals, which has 29 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00035022's enrollment target sits among peer trials
71 747th of 2000 higher than 1,252 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05452889 · 71 participants · Early Phase 1
PET Image in PAH Patients
- NCT05766943 · 71 participants · NA
Reduction of Myopotential Interference With Smart Pass in S-ICD Patients
- NCT06229678 · 71 participants · Early Phase 1
Ketones, SGLT2, HFrEF
- NCT06377566 · 71 participants · Phase 2
A Study of BV-AVD in People With Bulky Hodgkin Lymphoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia